Robotic vs. Non-Robotic Single-Site Hysterectomy: Marchand Institute’s New Meta-Analysis Provides Clarity on Surgical Outcomes
FOR IMMEDIATE RELEASE
MESA, Ariz. — July 23, 2021
We are very pleased to report that our latest paper, “A Systematic Review and Meta-Analysis of the Effect of Intraoperative Bupivacaine in Gynaecologic Surgery After 24 Hours or 9 Half-lives” has been published in the prestigious Journal of Obstetrics and Gynecology of Canada, and also appears online in the US government’s “Pubmed” website. We look forward to scholarly discussion of the impact this work may have!
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###
Related posts
